Sera Prognostics, Inc. (SERA) · Nov 4, 2026 · Earnings

Sera Prognostics earnings miss as PreTRM volume surges

Miss — EPS $(0.16) vs $(0.14) consensus; revenue $42K vs ~$75K–$80K consensus

Sera Prognostics’ Q3 earnings show surging PreTRM adoption and new Medicaid coverage, but revenue and EPS missed expectations.

Sera Prognostics is moving from clinical-evidence generation into early commercial execution for its PreTRM preterm-birth test, with Medicaid coverage and payer partnerships intended to turn clinical validation into reimbursed testing. Its prior quarter had already established Illinois Medicaid coverage, a fourth payer program, and a commercial ramp, so this filing mainly tests whether that groundwork is converting into revenue. The company previously said its cash position could fund operations through major commercialization milestones, reducing near-term financing pressure but not eliminating the need to prove demand.

The commercial indicators improved sharply, but the dollars are still very small. PreTRM test volume rose 54% sequentially and nearly fivefold from the first quarter, while ordering providers increased 34% sequentially and roughly threefold from the first quarter. Florida also became the second Medicaid state covering the test, bringing covered Medicaid lives to approximately 7 million. 〔0〕

The earnings score is a miss because adoption has not yet translated into the expected revenue. Revenue grew 163% year over year, but the $42,000 result was well below the roughly $75,000–$80,000 published consensus, and management attributed the shortfall to a higher mix of low- or non-reimbursed tests. The loss per share of $0.16 also missed the roughly $0.14 expected loss, although operating expenses declined 11% sequentially after June cost reductions.

The business story advanced, but the commercialization proof point remains incomplete. Florida coverage, Illinois’s $525 fee schedule without prior authorization, a larger sales team, European CE Mark submission activity, and additional clinical evidence all strengthen the infrastructure for future adoption. But the quarter still shows a company with only $42,000 of revenue against an $8.9 million operating-cost base, so the key transition from covered access to paid, reimbursed utilization has not yet been demonstrated.

Bottom line: Sera is building real commercial momentum and widening reimbursement access, but Q3 still missed the financial proof point the market was looking for. The filing is strategically encouraging yet earnings-negative, leaving the story dependent on whether covered test volume converts into materially higher revenue in fiscal 2027.

What to watch next

FY2027 multi-state payer pilot and Florida commercialization

Original filing on SEC EDGAR